Action PCSA PROCESSA PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Processa Pharmaceuticals, Inc.

Actions

PCSA

US74275C3043

Marché Fermé - Nasdaq
Autres places de cotation
 21:59:51 16/07/2024 		Varia. 5j. Varia. 1 janv.
1,75 USD +0,57 % Graphique intraday de Processa Pharmaceuticals, Inc. +6,06 % -73,85 %
11/06 Processa Pharmaceuticals, Inc. annonce des résultats d'efficacité positifs suite à l'évaluation préliminaire de l'essai de phase 1B avec Ngc-Cap dans le traitement du cancer gastro-intestinal CI
07/06 Les plus fortes baisses du prémarché MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
Processa Pharmaceuticals, Inc. Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1B Dose-Escalating Trial with Ngc-Cap in Gastrointestinal Cancer
Top Premarket Decliners
Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research
Certain Common Warrants of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.
Certain Restricted Stock Units of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.
Certain Options of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.
Certain Common Stock of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.
Top Premarket Decliners
Top Midday Gainers
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PCSA
  4. Actualités Processa Pharmaceuticals, Inc.
  5. Autres langues